证券代码：002932 证券简称：明德生物 公告编号：2023-040 武汉明德生物科技股份有限公司 关于 2019 年限制性股票激励计划预留授予限制性股票第二 个解锁期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 提请公司股东大会授权董事会办理股权激励相关事宜的议案》，公司独立董事对本 次激励计划及其他相关议案发表了明确同意的独立意见。 4、2020 年 5 月 28 日，公司召开第三届监事会第四次会议，审议通过了《关 于公司<2019 年限制性股票激励计划（草案修订稿）>及其摘要的议案》《关于公 司<2019 年限制性股票激励计划实施考核管理办法（修订稿）>的议案》和《关于 2019 年限制性股票激励计划激励对象名单（修订稿）的议案》。 5、2020 年 6 月 2 日至 2020 年 6 月 12 日，公司对本激励计划首次授予激励对 象的姓名及职务在公司内部 OA 进行了公示，截至 2020 年 6 月 12 日公示期满， 公司监事会未收到任何异议或不良反映，无反馈记录。2020 年 8 月 14 日， ...

证券代码：002932 证券简称：明德生物 公告编号：2023-037 武汉明德生物科技股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉明德生物科技股份有限公司（以下简称"公司"）第四届董事会第六次 会议于 2023 年 8 月 10 日以现场及通讯相结合的方式在公司会议室召开，会议通 知已于 2023 年 8 月 7 日以电子邮件、电话通讯等形式发出。本次会议应到董事 7 名，实际出席公司会议的董事 7 名，会议由董事长陈莉莉女士主持，公司监事、 高级管理人员列席了本次会议，会议的召集和召开符合《中华人民共和国公司法》 等法律法规及公司章程的规定。 二、董事会会议审议情况 1、审议并通过《关于 2019 年限制性股票激励计划首次授予第三个解除限 售期及预留授予第二个解除限售期解除限售条件成就的议案》 根据《上市公司股权激励管理办法》、《武汉明德生物科技股份有限公司 2019 年限制性股票激励计划（草案修订稿）》、《武汉明德生物科技股份有限 公司 2019 年限制性股票激励计划实施考核管 ...

武汉明德生物科技股份有限公司监事会 关于 2019 年限制性股票激励计划首次授予第三个解除限售期及 预留授予第二个解除限售期可解除限售激励对象名单的核查意 见 武汉明德生物科技股份有限公司（以下简称"公司"）监事会根据《中华人 民共和国公司法》（以下简称"公司法"）、《中华人民共和国证券法》（以下简称 "证券法"）、《上市公司股权激励管理办法》（以下简称"管理办法"）等有关法 律、法规及规范性文件和公司《2019 年限制性股票激励计划（草案修订稿）》 （以下简称"《激励计划》"）的规定，对公司 2019 年限制性股票激励计划首次 授予第三个限售期及预留授予第二个限售期可解除限售激励对象名单进行了核 查并发表如下意见： 1、公司符合《管理办法》等法律法规、规范性文件规定的实施股权激励计 划的情形，公司具备实施股权激励计划的主体资格，符合《激励计划》中对首 次授予第三个解除限售期及预留授予第二个解除限售期解除限售条件的要求， 未发生《激励计划》中规定的不得解除限售的情形； 2、公司 2019 年限制性股票激励计划的激励对象不存在《管理办法》规定 的不得成为激励对象的情形： （1）最近 12 个月内被证券交易所认定 ...

因此，我们一致同意公司按照公司 2019 年限制性股票激励计划的相关规定 为 54 名激励对象办理相应的解除限售事宜。 （以下无正文） （此页无正文，为武汉明德生物科技股份有限公司独立董事关于相关事项意见 之签署页） 根据《中华人民共和国公司法》、《上市公司独立董事规则》、《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》及《公司章程》等 相关规定，我们作为武汉明德生物科技股份有限公司（以下简称"公司"）的独 立董事，对提交公司第四届董事会第六次会议审议的相关议案进行了审议，现就 相关议案所涉及的事宜发表独立意见如下： 独立董事关于第四届董事会第六次会议 一、关于 2019 年限制性股票激励计划首次授予第三个解除限售期及预留 授予第二个解除限售期解除限售条件成就的独立意见 相关审议事项的独立意见 经审核，我们认为，公司 2019 年限制性股票激励计划首次授予第三个解除 限售期及预留授予第二个解除限售期解除限售条件已经成就，公司及 54 名激励 对象均未发生激励计划中规定的不得解除限售的情形，本次可解除限售的激励对 象主体资格合法、有效，其中：52 名首次授予激励对象第三个解除限售期个人 ...

公司于 2023 年 8 月 10 日召开了第四届董事会第六次会议，审议通过了《关 于 2019 年限制性股票激励计划首次授予第三个解除限售期及预留授予第二个解 除限售期解除限售条件成就的议案》。现将有关情况公告如下： 一、已履行的相关审批程序 证券代码：002932 证券简称：明德生物 公告编号：2023-039 武汉明德生物科技股份有限公司 关于 2019 年限制性股票激励计划解除限售条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）2019 年限制性股 票激励计划（以下简称"激励计划"）首次授予第三个限售期及预留授予第二个 限售期即将届满且解除限售条件已经成就，不存在不能解除限售或不得成为激励 对象的情形。本次符合解除限售的激励对象共 54 名，其中：52 名首次授予激励 对象解除限售的限制性股票数量为 1,940,414 股；2 名预留授予激励对象解除限 售的限制性股票数量为 122,772 股，解除限售的限制性股票数量共 2,063,186 股， 约占目前公司股本总额 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况： 武汉明德生物科技股份有限公司(以下简称"公司")第四届监事会第六次会议 通知于2023年8月7日以电子邮件和专人送达的方式通知全体监事。本次会议于2023 年8月10日在公司会议室以现场会议方式召开。本次会议应到监事3人，实到监事3人， 全体监事均亲自出席会议。符合《中华人民共和国公司法》的规定和公司《公司章程》 的要求。本次会议由监事会主席杨汉玲女士主持，公司高级管理人员列席了本次会议。 本次监事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定。 二、监事会会议审议情况： 1、审议并通过《关于 2019 年限制性股票激励计划首次授予第三个解除限售期 及预留授予第二个解除限售期解除限售条件成就的议案》 证券代码：002932 证券简称：明德生物 公告编号：2023-038 武汉明德生物科技股份有限公司 第四届监事会第六次会议决议公告 三、备查文件： 1 1、经与会监事签字并加盖监事会印章的第四届监事会第六次会议决议； 2、深交所要求的其他文件。 特此公告。 ...

证券代码：002932 证券简称：明德生物 公告编号：2023-028 武汉明德生物科技股份有限公司 关于参加 2023 年湖北辖区上市公司投资者网上集体接待日暨 2022 年度业绩说明会活动的公告 特别提示： 1、会议召开时间：2023 年 5 月 25 日（星期四）14：30-16：35 2、会议召开方式：网络方式 一、活动安排 为进一步加强武汉明德生物科技股份有限公司（以下简称"公司"）与投 资者互动交流，公司将于 2023 年 5 月 25 日参加由湖北证监局主办的"2023 年 湖北辖区上市公司投资者集体接待日暨 2022 年度业绩说明会活动"，届时将通 过网络远程的方式与广大投资者就公司发展战略、经营状况、公司治理等投资 者关注的问题进行交流与沟通。 二、召开的时间、方式 召开时间：2023 年 5 月 25 日（星期四）14：30-16：35 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国金证券股份有限公司保荐代表人：林尚研先生 会议方式：网络远程形式，通过"全景网"（https://ir.p5w.net/c/002932） 召开本次说明会活 ...

证券代码：002932 证券简称：明德生物 公告编号：2023-028 武汉明德生物科技股份有限公司 关于参加 2023 年湖北辖区上市公司投资者网上集体接待日暨 2022 年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、会议召开时间：2023 年 5 月 25 日（星期四）14：30-16：35 2、会议召开方式：网络方式 一、活动安排 为进一步加强武汉明德生物科技股份有限公司（以下简称"公司"）与投 资者互动交流，公司将于 2023 年 5 月 25 日参加由湖北证监局主办的"2023 年 湖北辖区上市公司投资者集体接待日暨 2022 年度业绩说明会活动"，届时将通 过网络远程的方式与广大投资者就公司发展战略、经营状况、公司治理等投资 者关注的问题进行交流与沟通。 二、召开的时间、方式 召开时间：2023 年 5 月 25 日（星期四）14：30-16：35 会议方式：网络远程形式，通过"全景网"（https://ir.p5w.net/c/002932） 召开本次说明会活动。 三、参加人员 董事长、总经理：陈莉莉女 ...

Financial Performance - The company's revenue for Q1 2023 was ¥372,402,234.89, a decrease of 85.03% compared to ¥2,487,211,050.62 in the same period last year[4] - Net profit attributable to shareholders was ¥75,450,691.09, down 94.57% from ¥1,389,036,851.52 year-on-year[4] - The net cash flow from operating activities was -¥341,182,026.20, a decline of 217.75% compared to ¥289,745,937.37 in the previous year[4] - Basic earnings per share dropped to ¥0.49, a decrease of 94.60% from ¥9.07 in the same period last year[4] - Total assets at the end of the reporting period were ¥8,870,151,037.78, down 3.49% from ¥9,190,948,425.72 at the end of the previous year[4] Sales and Market Demand - The company reported a significant decline in sales revenue due to a decrease in demand for COVID-19 testing products[9] - The cash received from sales of goods and services was ¥398,357,857.78, a decrease of 73.17% compared to ¥1,484,673,582.69 in the previous year[10] - User data indicates that the number of active users for the company's diagnostic products has reached 1.2 million, up 15% compared to the previous quarter[18] - User data indicates a growing customer base, with a 30% increase in the number of active users compared to the previous quarter[20] - User data showed an increase in the number of tests conducted, reaching 1.5 million tests in Q1 2023, up from 1.2 million in Q1 2022, representing a growth of 25%[22] Product Development and Innovation - The company has obtained a total of 307 product registration certificates, including 10 Class III medical device certificates and 279 Class II medical device certificates[14] - The company has launched new products such as the QFT9000 dry fluorescence immunoassay analyzer and the PT1000 blood gas analyzer, both classified as Class II medical devices[14] - The company reported a total of 48 new product registrations, including various immunoassay kits and analyzers, with a focus on cardiovascular and thyroid-related diagnostics[15] - The heart-type fatty acid-binding protein (H-FABP) test kit (immunochromatography method) was registered with a validity until May 2026, indicating ongoing product lifecycle management[16] - The company is expanding its product line with the introduction of new testing kits, including those for D-Dimer and procalcitonin, which are critical for cardiovascular and infection diagnostics[16] Strategic Focus and Market Expansion - The company plans to continue focusing on research and development to adapt to changing market conditions and consumer needs[10] - The company is focused on expanding its market presence through new product registrations and technological advancements[14] - The company aims to enhance its market presence by developing advanced testing technologies, such as magnetic chemiluminescence immunoassay methods, to improve diagnostic accuracy[15] - Market expansion efforts are underway, targeting Southeast Asia, with plans to enter three new countries by the end of 2023[18] - The company is exploring potential acquisitions to enhance its product portfolio, focusing on companies with complementary technologies[18] Financial Outlook and Projections - The company has provided a positive outlook for the remainder of 2023, projecting a revenue growth of 20% to 25% for the full year[18] - Future guidance includes maintaining a gross margin of approximately 60% for the upcoming quarters, supported by efficient production processes[20] - The company has set a performance guidance of achieving a net profit margin of 20% for the fiscal year 2023[22] - Future outlook indicates a projected revenue growth of 30% for the next quarter, driven by new product launches and market expansion strategies[22] - The company aims to achieve a gross margin of 60% on new product lines, leveraging cost-effective manufacturing processes[24] Research and Development Investments - The company is investing in R&D for advanced diagnostic technologies, with a budget allocation of 30 million RMB for the year[18] - Research and development expenses for Q1 2023 were CNY 33,184,792.04, an increase from CNY 28,800,168.74 in Q1 2022[33] - The company is focusing on R&D for advanced diagnostic technologies, with an investment of 10 million RMB allocated for new product development in 2023[24] - The company is actively engaged in research and development of new testing kits, including those for monkeypox and various gene mutations related to SARS-CoV-2[27] - The company plans to invest in research and development to innovate and improve existing diagnostic products, ensuring they meet evolving market needs[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,045[12] - The top shareholder, Chen Lili, holds 27.04% of shares, totaling 42,227,446 shares[12] - The top 10 shareholders collectively hold a significant portion of the company's shares, indicating concentrated ownership[12] - The company has a diverse range of shareholders, including both individual and institutional investors[12] - The company has established relationships among some shareholders, indicating potential strategic alliances[13]

Market Risks and Challenges - The company faced significant risks due to policy changes in the in vitro diagnostic industry, particularly following the global decline in demand for COVID-19 testing products, which could impact future performance [5]. - The company acknowledges risks associated with fundraising investment projects due to market changes, policy shifts, and potential operational issues [18]. - The company is at risk of price reductions in in vitro diagnostic products due to centralized procurement policies initiated by the National Medical Insurance Administration [199]. - In 2023, the average price reduction for selected coagulation and myocardial infarction clinical testing reagents reached 40.16%, with some products seeing reductions of up to 49.59% [200]. Financial Performance - The company's operating revenue for 2022 was ¥10,530,277,815.19, representing a 272.12% increase compared to ¥2,829,829,546.30 in 2021 [6]. - The net profit attributable to shareholders for 2022 was ¥4,208,432,815.25, a 197.79% increase from ¥1,413,224,434.03 in 2021 [6]. - The cash flow from operating activities for 2022 was ¥4,012,848,413.21, up 256.06% from ¥1,127,006,147.61 in 2021 [6]. - The basic earnings per share for 2022 was ¥27.50, a 176.38% increase from ¥9.95 in 2021 [6]. - The total assets at the end of 2022 were ¥9,190,948,425.72, reflecting a 168.97% increase from ¥3,417,089,810.18 at the end of 2021 [6]. - The weighted average return on equity for 2022 was 87.36%, up from 77.04% in 2021 [6]. Research and Development - The company plans to increase R&D investment and expand its product lines to mitigate risks associated with reliance on single product categories [5]. - The company has committed to maintaining high R&D investment to ensure core technological capabilities and innovation in product development [17]. - The company is investing in R&D for new technologies, with a budget allocation of 100 million RMB for the development of advanced immunoassay methods [110]. - The company has achieved a research and development investment of 38,836.02 million yuan in 2022, representing a year-on-year increase of 192.56% [127]. Product Development and Innovation - The company is actively involved in the development of new products and technologies related to COVID-19 diagnostics, including antigen and antibody tests [33]. - The company has launched a new COVID-19 antigen test kit, which received regulatory approval and was successfully procured by multiple provinces in 2022 [105]. - The company has developed a rich product matrix in various lines, including immunoassay, molecular diagnostics, blood gas, and coagulation products [124]. - The company has launched multiple new diagnostic kits, including cardiac troponin T (cTnT) and myoglobin (MYO) test kits, with a validity period extending until 2026 [114]. - The company is focusing on expanding its product offerings in the immunoassay market, particularly with magnetic microparticle chemiluminescence immunoassay methods [114]. Market Expansion and Strategy - The company aims to enhance its competitive edge by improving product quality, sales networks, and overseas market presence amid intensifying market competition [14]. - The company plans to increase its market share in molecular diagnostics and expand its product line, including fully automated nucleic acid detection systems and differentiated POCT molecular detection devices [185]. - Market expansion plans include entering Southeast Asian markets, targeting a market share of 10% within the next two years [111]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in molecular diagnostics [110]. Regulatory Compliance and Quality Management - The company’s products are subject to stringent regulatory requirements, including CE certification for the EU and FDA approval for the US market, which can take 12-18 months [62][63]. - The company’s quality management system adheres to ISO13485 standards, ensuring compliance and reliability throughout the product lifecycle [134]. - The company reported a commitment to maintaining high standards of product quality and safety in its diagnostic offerings, ensuring compliance with regulatory requirements [95]. Customer Engagement and Market Position - The company emphasizes a customer-centric approach and continuous innovation to meet the evolving needs of healthcare services [80]. - The company has established a comprehensive service platform for clinical molecular diagnostics and serological testing, serving over 100 medical clients [103]. - The company has been recognized for its contributions to the construction of smart chest pain centers, with multiple hospitals using its solutions receiving awards [106]. Operational Efficiency and Cost Management - The company reported a gross margin of 60%, indicating strong operational efficiency and cost management [112]. - The company aims to improve operational efficiency, targeting a reduction in production costs by 15% through automation [110]. - The company’s financial expenses decreased significantly, showing a reduction of 494.15% due to increased interest income from deposits [152]. Strategic Partnerships and Collaborations - A new strategic partnership has been established with a leading healthcare provider to enhance distribution channels, expected to increase market penetration by 30% [111]. - The company is establishing a joint venture with Junlian Capital to focus on investment and mergers in innovative medical sectors, supporting diversified business development [196]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB [112]. - The company has set ambitious business development goals for the next three years, focusing on pathogen diagnostics and infectious disease diagnostics to enhance its competitive advantage [183].